28,812 Shares in IQVIA Holdings Inc. $IQV Acquired by Foyston Gordon & Payne Inc

by · The Markets Daily

Foyston Gordon & Payne Inc bought a new stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 28,812 shares of the medical research company’s stock, valued at approximately $5,630,000.

A number of other large investors have also made changes to their positions in the business. Apella Capital LLC boosted its position in shares of IQVIA by 5.1% in the 1st quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after purchasing an additional 58 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock worth $1,080,000 after acquiring an additional 60 shares in the last quarter. Private Advisor Group LLC increased its holdings in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares in the last quarter. Breakwater Capital Group raised its position in shares of IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after purchasing an additional 64 shares during the last quarter. Finally, Keybank National Association OH grew its position in IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 67 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 12,913 shares of company stock valued at $3,098,793. Insiders own 1.70% of the company’s stock.

IQVIA Stock Up 1.6%

IQVIA stock opened at $260.17 on Friday. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.40. The firm has a market cap of $42.82 billion, a price-to-earnings ratio of 32.28, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The business’s 50-day moving average price is $213.32 and its 200 day moving average price is $187.52. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the company earned $2.81 EPS. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has authorized a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on IQV shares. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. JPMorgan Chase & Co. increased their price objective on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, BMO Capital Markets increased their price target on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Read Our Latest Research Report on IQVIA

About IQVIA

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).